HbA1c measurement using capillary blood in epidemiological studies: a scoping review of technologies and approaches
Breternitz et al.
The finding, in our words
This scoping review identified 15 distinct technologies for measuring HbA1c from capillary blood, with point-of-care devices requiring only 2 to 10 µL and delivering results within minutes. However, diagnostic accuracy varied widely between studies and devices, and most evidence comes from high-income countries, indicating gaps in validation for low- and middle-income settings where decentralised screening is most needed.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
Heughebaert et al., Clinical chemistry and laboratory medicine (paywalled) · source ↗
The study validated a semi-quantitative protocol for Epstein-Barr virus serology using dried blood spots, demonstrating 98.8% sensitivity and 96.5% specificity compared to paired venous serum samples. The successful validation in a self-sampling cohort confirms the suitability of this patient-centric microsampling approach for large-scale seroprevalence studies and decentralised trials.
This study validated a dried blood spot method for tacrolimus monitoring and demonstrated agreement with venous whole blood measurements in kidney transplant recipients. It also found that dried blood spot analysis of the biomarker CXCL-10 was elevated in patients experiencing rejection or infection, supporting its use for decentralised monitoring.